Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma

  • Authors:
    • Shuhong Gao
    • Zhengzheng Shi
    • Xin Li
    • Wenzhi Li
    • Yiling Wang
    • Zhiming Liu
    • Jie Jiang
  • View Affiliations

  • Published online on: February 13, 2018     https://doi.org/10.3892/or.2018.6265
  • Pages: 1919-1929
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Fatostatin, a chemical inhibitor of the sterol regulatory element‑binding protein (SREBP) pathway, has been reported to possess high antitumor activity against prostate and pancreatic cancer. The main aim of the present study was to investigate the effects and mechanism of fatostatin in endometrial carcinoma (EC). In the present study, we determined that fatostatin inhibited EC cell viability and colony formation capacity, decreased the invasive and migratory capacities of EC cells, induced EC cell cycle arrest at the G2/M phase and stimulated caspase‑mediated apoptosis of EC cells. In addition, fatostatin significantly decreased the protein expression levels of nuclear SREBPs and their downstream genes and increased the protein expression levels of cleaved caspase‑9, caspase‑3 and PARP in EC cells. In addition, the mRNA expression levels of SREBP‑controlled downstream genes were also significantly downregulated. The quantification assays of fatty acids and total cholesterol revealed that the levels of free fatty acids and total cholesterol in EC cells were decreased. The present study indicated that fatostatin exhibited antitumor effects by blocking SREBP‑regulated metabolic pathways and inducing caspase‑mediated apoptosis in EC and may be a potent therapeutic strategy for the treatment of EC.
View Figures
View References

Related Articles

Journal Cover

April-2018
Volume 39 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gao S, Shi Z, Li X, Li W, Wang Y, Liu Z and Jiang J: Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma. Oncol Rep 39: 1919-1929, 2018.
APA
Gao, S., Shi, Z., Li, X., Li, W., Wang, Y., Liu, Z., & Jiang, J. (2018). Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma. Oncology Reports, 39, 1919-1929. https://doi.org/10.3892/or.2018.6265
MLA
Gao, S., Shi, Z., Li, X., Li, W., Wang, Y., Liu, Z., Jiang, J."Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma". Oncology Reports 39.4 (2018): 1919-1929.
Chicago
Gao, S., Shi, Z., Li, X., Li, W., Wang, Y., Liu, Z., Jiang, J."Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma". Oncology Reports 39, no. 4 (2018): 1919-1929. https://doi.org/10.3892/or.2018.6265